Endothelial dysfunction and hyperhomocysteinemia in Parkinson's disease: Flow-mediated dilation study

Yoon, Jung Han; Lee, Jin Soo; Yong, Seok Woo; Hong, Ji Man; Lee, Phil Hyu

doi:10.1002/mds.26005

Cited by 22 publications

(9 citation statements)

References 30 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study is the first that used peripheral arterial tonometry (PAT). Our results are consistent with FMD studies, showing lower RHI in PD subjects compared to controls [11,12].…”

Section: Discussionsupporting

confidence: 93%

“…l -dopa therapy exhibits increased levels of homocysteine that is considered a modest independent risk factor for vascular disease, causing endothelial damage and atherogenesis [ 15 , 24 ]. Yoon et al concluded that EF, as assessed by the FMD, may be associated with chronic l -dopa treatment in patients with PD [ 11 ]. Our results suggest no significant association between RHI and l -dopa treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Endothelial dysfunction (ED) is an initial process and a key component of atherogenesis [ 10 ]. Previous studies indicated that endothelial function (EF), as assessed by the flow-mediated dilation (FMD), was significantly decreased in PD patients [ 11 , 12 ]. Several possible mechanisms are explaining the impairment of EF in PD.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Impairment of endothelial function in Parkinson’s disease

Kollár

Blaho²,

Valovičová

et al. 2022

BMC Res Notes

View full text Add to dashboard Cite

Objective There are conflicting data regarding the relationship between Parkinson’s disease (PD) and the atherosclerotic process. This study aimed to compare endothelial function in patients with PD and matched controls. In PD subjects, we searched for factors contributing to endothelial dysfunction as well. Traditional vascular risk factors, PD characteristics, and PD medication were considered. Results We prospectively enrolled 41 patients with PD and 41 controls matched for age, sex, body mass index, and vascular risk factors. Endothelial function (EF) was assessed using peripheral arterial tonometry (EndoPAT 2000 device) and expressed as reperfusion hyperemia index (RHI). Clinical characteristics including PD medication were recorded. RHI was non-significantly lower in the PD group than in controls (1.8 ± 0.5 vs. 1.9 ± 0.5, p = 0.478). In PD patients, in linear regression analysis, smoking (beta = −0.453, p = 0.008) and use of dopamine agonists (beta = -0.365, p = 0.030) were significant contributors in a model predicting RHI. Despite non-significant differences in endothelial dysfunction between PD patients and controls, our results suggest an association between smoking, dopamine agonists, and impaired EF in PD patients. The small sample size, as well as the absence of an extended search for traditional and non-traditional vascular risk factors, are the most important factors limiting the interpretation of the current results.

show abstract

“…Our study is the first that used peripheral arterial tonometry (PAT). Our results are consistent with FMD studies, showing lower RHI in PD subjects compared to controls [11,12].…”

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impairment of endothelial function in Parkinson’s disease

Kollár

Blaho²,

Valovičová

et al. 2022

BMC Res Notes

View full text Add to dashboard Cite

show abstract

“…Regarding PD, a decreased FMD was found in patients treated with L-dopa compared to patients treated with L-dopa and entacapone, untreated patients, and control subjects. An inverse relationship has been demonstrated between FMD and hyperhomocysteinemia, which could explain the FMD reduction observed in the L-dopa group (Yoon et al, 2014). Overall, limited and conflicting evidences are available so far, mainly due to the advanced age and reduced cooperation of the patients.…”

Section: Identifying and Targeting Vascular Dysfunction In Neurodegen...mentioning

confidence: 99%

Connecting vascular aging and frailty in Alzheimer’s disease

Ramini

Giuliani

Recchioni

et al. 2021

Mechanisms of Ageing and Development

View full text Add to dashboard Cite

“…Endothelial dysfunction in PD may result from chronic L‐DOPA treatments (Yoon et al . ) and even acute administration increases regional cerebral blood flow and BBB permeability (Ohlin et al . ).…”

Section: Endothelial Activation and Dysfunction In Brain Disordersmentioning

confidence: 99%

Vascular inter‐regulation of inflammation: molecular and cellular targets for CNS therapy

Machado-Pereira

Santos

Bernardino

2017

Journal of Neurochemistry

View full text Add to dashboard Cite

Angiogenesis and inflammation are clearly interconnected and interdependent processes that are dysregulated in a series of systemic and brain pathologies. Herein, key aspects regarding endothelial cell function and tissue remodelling that are particularly affected or aggravated by inflammation are presented. Most importantly, the cellular and molecular mechanisms involved in the vascular regulation of the inflammatory processes occurring in several brain disorders and how they impact on disease/injury progression are detailed, highlighting potential targets for therapy. Finally, nanomedicine-based approaches designed to overcome limitations pertaining to low systemic bioavailability, light, pH and temperature sensitivity and/or rapid degradation of these targets, and to optimize their mode of action are discussed. Ultimately, we expect this review to provide new insight and to suggest novel approaches for the treatment of blood-brain barrier dysfunction per se or as a means to treat the injured or diseased central nervous system.

show abstract

Endothelial dysfunction and hyperhomocysteinemia in Parkinson's disease: Flow-mediated dilation study

Abstract: Our findings indicate that endothelial dysfunction may be associated with chronic l-dopa treatment in patients with PD.

Cited by 22 publications

References 30 publications

Impairment of endothelial function in Parkinson’s disease

Impairment of endothelial function in Parkinson’s disease

Connecting vascular aging and frailty in Alzheimer’s disease

Vascular inter‐regulation of inflammation: molecular and cellular targets for CNS therapy

Contact Info

Product

Resources

About